e-learning
resources
Munich 2006
Monday 04.09.2006
Pulmonary arterial hypertension: from bench back to bedside
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The pattern of response in acute vasodilator test in portopulmonary hypertension (PoPH)
G. L. Ricci, M. T. Melgosa, F. Burgos, J. L. Valera, S. Pizarro, J. Roca, R. Rodriguez-Roisin, J. A. Barbera‘ (Rome, Italy; Barcelona, Spain)
Source:
Annual Congress 2006 - Pulmonary arterial hypertension: from bench back to bedside
Session:
Pulmonary arterial hypertension: from bench back to bedside
Session type:
Poster Discussion
Number:
3156
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. L. Ricci, M. T. Melgosa, F. Burgos, J. L. Valera, S. Pizarro, J. Roca, R. Rodriguez-Roisin, J. A. Barbera‘ (Rome, Italy; Barcelona, Spain). The pattern of response in acute vasodilator test in portopulmonary hypertension (PoPH). Eur Respir J 2006; 28: Suppl. 50, 3156
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Acute effect of sildenafil (PDE-5) on cardiopulmonary interactions in patients with pulmonary arterial hypertension (PAH) secondary to pulmonary fibrosis
Source: Annual Congress 2008 - Pulmonary hypertension II
Year: 2008
Sildenafil effects on 1-year survival of patients with idiopathic pulmonary arterial hypertension (IPAH)
Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension
Year: 2005
Sildenafil treatment for portopulmonary hypertension
Source: Eur Respir J 2006; 28: 563-567
Year: 2006
Novel hypoxia system to assess endothelial dysfunction in chronic thromboembolic pulmonary hypertension (CTEPH)
Source: Virtual Congress 2021 – Pathogenesis and pathophysiology of pulmonary hypertension
Year: 2021
Acute vasodilator response in different forms of pre-capillary pulmonary hypertension
Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment
Year: 2013
Experience with inhaled iloprost and bosentan in portopulmonary hypertension
Source: Eur Respir J 2007; 30: 1096-1102
Year: 2007
Effect of riociguat on haemodynamic parameters and exercise capacity in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH)
Source: Annual Congress 2009 - Clinical management of pulmonary arterial hypertension
Year: 2009
Endothelin-1 and endothelin-3 plasma levels in severe idiopathic pulmonary arterial hypertension
Source: Annual Congress 2005 - Pulmonary hypertension: pathophysiology
Year: 2005
Contrasting physiological responses to the six minute walk test in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and idiopathic pulmonary arterial hypertension (IPAH)
Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology
Year: 2016
Hemodynamic effects of sildenafil in pulmonary arterial hypertension (PAH) patients
Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension
Year: 2005
Inhaled iloprost is a potent acute pulmonary vasodilator in HIV-related severe pulmonary hypertension
Source: Eur Respir J 2004; 23: 321-326
Year: 2004
Sitaxsentan for pulmonary arterial hypertension (PAH) patients with clinical deterioration or significantly abnormal liver function test on bosentan
Source: Eur Respir J 2005; 26: Suppl. 49, 563s
Year: 2005
Long-term treatment of pulmonary hypertension with aerosolized iloprost
Source: Eur Respir J 2001; 17: 8-13
Year: 2001
Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension
Source: Eur Respir J 2009; 33: 92-98
Year: 2009
Pulmonary hypertension in COPD
Source: Eur Respir J 2008; 32: 1371-1385
Year: 2008
Portopulmonary hypertension
Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-39-1, page=129
Year: 2005
Effects of endothelin receptor antagonist (ERA) bosentan on myocardial glucose metabolism in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH)
Source: International Congress 2017 – PAH and CTEPH
Year: 2017
Portopulmonary hypertension and hepatopulmonary syndrome: a clinician-oriented overview
Source: Eur Respir Rev 2012 21:223-233
Year: 2012
Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension
Source: Eur Respir J 2013; 41: 96-103
Year: 2013
Effects of amlodipine on pulmonary haemodynamics in pulmonary hypertension (PH) secondary to chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2002; 20: Suppl. 38, 27s
Year: 2002
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept